Table 2.
Primary outcomes, overall and by condition (95% uncertainty interval)
| Condition | # Treated | Mean QALYs gained | Mean cost per QALY (USD, PPP) | ||
|---|---|---|---|---|---|
| Discount factor | 0% | 3% | 0% | 3% | |
| All | 69 | 14.4 (12.4–15.8) | 6.3 (5.2–7.2) | 383 (262–588) | 488 (339–747) |
| Skin cancer | 11 | 3.8 (2.5–5.3) | 3.0 (2.0–4.1) | 513 (371–781) | 583 (421–889) |
| Cataract | 13 | 2.0 (1.3–2.8) | 1.2 (0.8–1.8) | 1284 (809–1995) | 1506 (949–2339) |
| Severe | 5 | 4.4 (3.1–6.3) | 2.6 (1.8–3.7) | 591 (420–850) | 713 (507–1025) |
| Moderate | 8 | 0.4 (0.3–0.7) | 0.3 (0.2–0.6) | 1717 (1051–2711) | 2001 (1225–3160) |
| Hernia | 6 | 30.3 (28.9–32.1) | 9.9 (8.9–11.1) | 31 (27–36) | 63 (55–73) |
| Severe | 2 | 15.7 (14.0–17.9) | 9.6 (8.3–11.2) | 66 (54–80) | 86 (69–107) |
| Moderate | 4 | 37.7 (36.4–39.2) | 10.0 (9.3–11.0) | 14 (13–14) | 52 (47–56) |
| Heart conditions | 6 | 26.7 (26.1–27.4) | 9.1 (8.7–9.7) | 51 (44–61) | 137 (116–165) |
| Severe | 4 | 29.6 (29.1–30.1) | 10.1 (9.6–10.7) | 40 (39–40) | 113 (108–119) |
| Moderate | 2 | 20.8 (20.2–21.9) | 7.1 (6.8–7.7) | 67 (50–93) | 173 (129–234) |
| Epilepsy | 8 | 24.5 (21.3–26.9) | 8.9 (6.9–10.4) | 44 (41–53) | 103 (90–134) |
| Severe | 5 | 20.0 (16.8–21.4) | 8.8 (6.8–10.0) | 63 (58–77) | 137 (121–180) |
| Less severe | 3 | 32.0 (28.8–36.0) | 9.0 (7.2–11.2) | 13 (12–14) | 46 (37–58) |
| Gall bladder conditions | 4 | 26.2 (23.5–29.2) | 11.2 (9.5–13.2) | 17 (16–19) | 41 (35–47) |
| Cholecystitis | 3 | 29.2 (26.0–32.7) | 12.5 (10.5–14.9) | 15 (14–17) | 36 (30–43) |
| Cholelithiasis | 1 | 17.2 (16.2–18.4) | 7.3 (6.6–8.1) | 23 (21–25) | 54 (49–60) |
| Thyroid conditions | 4 | 7.0 (4.5–9.4) | 3.8 (2.5–5.2) | 56 (42–88) | 100 (74–157) |
| Kidney stones | 6 | 4.0 (2.7–5.6) | 2.1 (1.4–2.9) | 304 (218–444) | 568 (407–830) |
| Breast cancer | 5 | 29.9 (29.8–30.0) | 18.4 (18.3–18.6) | 77 (77–78) | 124 (123–124) |
| Cryptorchidism | 6 | 13.6 (5.4–13.6) | 6.0 (2.4–6.0) | 57 (57–144) | 129 (129–324) |